Cargando…
A novel cuproptosis-related lncRNA signature predicts prognosis and therapeutic response in bladder cancer
Bladder cancer (BC) ranks the tenth in the incidence of global tumor epidemiology. LncRNAs and cuproptosis were discovered to regulate the cell death. Herein, we downloaded transcriptome profiling, mutational data, and clinical data on patients from The Cancer Genome Atlas (TCGA). High- and low-risk...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9845412/ https://www.ncbi.nlm.nih.gov/pubmed/36685947 http://dx.doi.org/10.3389/fgene.2022.1082691 |
_version_ | 1784870902780919808 |
---|---|
author | Cai, Jinming Xie, Haoran Yan, Yilin Huang, Zhengnan Tang, Pengfei Cao, Xiangqian Wang, Zeyi Yang, Chenkai Wen, Jiling Tan, Mingyue Zhang, Fang Shen, Bing |
author_facet | Cai, Jinming Xie, Haoran Yan, Yilin Huang, Zhengnan Tang, Pengfei Cao, Xiangqian Wang, Zeyi Yang, Chenkai Wen, Jiling Tan, Mingyue Zhang, Fang Shen, Bing |
author_sort | Cai, Jinming |
collection | PubMed |
description | Bladder cancer (BC) ranks the tenth in the incidence of global tumor epidemiology. LncRNAs and cuproptosis were discovered to regulate the cell death. Herein, we downloaded transcriptome profiling, mutational data, and clinical data on patients from The Cancer Genome Atlas (TCGA). High- and low-risk BC patients were categorized. Three CRLs (AL590428.1, AL138756.1 and GUSBP11) were taken into prognostic signature through least absolute shrinkage and selection operator (LASSO) Cox regression. Worse OS and PFS were shown in high-risk group (p < 0.05). ROC, independent prognostic analyses, nomogram and C-index were predicted via CRLs. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis indicated IncRNAs play a biological role in BC progression. Immune-related functions showed the high-risk group received more benefit from immunotherapy and had stronger immune responses, and the overall survival was better (p < 0.05). Finally, a more effective outcome (p < 0.05) was found from clinical immunotherapy via the TIDE algorithm and many potential anti-tumor drugs were identified. In our study, the cuproptosis-related signature provided a novel tool to predict the prognosis in BC patients accurately and provided a novel strategy for clinical immunotherapy and clinical applications. |
format | Online Article Text |
id | pubmed-9845412 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-98454122023-01-19 A novel cuproptosis-related lncRNA signature predicts prognosis and therapeutic response in bladder cancer Cai, Jinming Xie, Haoran Yan, Yilin Huang, Zhengnan Tang, Pengfei Cao, Xiangqian Wang, Zeyi Yang, Chenkai Wen, Jiling Tan, Mingyue Zhang, Fang Shen, Bing Front Genet Genetics Bladder cancer (BC) ranks the tenth in the incidence of global tumor epidemiology. LncRNAs and cuproptosis were discovered to regulate the cell death. Herein, we downloaded transcriptome profiling, mutational data, and clinical data on patients from The Cancer Genome Atlas (TCGA). High- and low-risk BC patients were categorized. Three CRLs (AL590428.1, AL138756.1 and GUSBP11) were taken into prognostic signature through least absolute shrinkage and selection operator (LASSO) Cox regression. Worse OS and PFS were shown in high-risk group (p < 0.05). ROC, independent prognostic analyses, nomogram and C-index were predicted via CRLs. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis indicated IncRNAs play a biological role in BC progression. Immune-related functions showed the high-risk group received more benefit from immunotherapy and had stronger immune responses, and the overall survival was better (p < 0.05). Finally, a more effective outcome (p < 0.05) was found from clinical immunotherapy via the TIDE algorithm and many potential anti-tumor drugs were identified. In our study, the cuproptosis-related signature provided a novel tool to predict the prognosis in BC patients accurately and provided a novel strategy for clinical immunotherapy and clinical applications. Frontiers Media S.A. 2023-01-04 /pmc/articles/PMC9845412/ /pubmed/36685947 http://dx.doi.org/10.3389/fgene.2022.1082691 Text en Copyright © 2023 Cai, Xie, Yan, Huang, Tang, Cao, Wang, Yang, Wen, Tan, Zhang and Shen. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Genetics Cai, Jinming Xie, Haoran Yan, Yilin Huang, Zhengnan Tang, Pengfei Cao, Xiangqian Wang, Zeyi Yang, Chenkai Wen, Jiling Tan, Mingyue Zhang, Fang Shen, Bing A novel cuproptosis-related lncRNA signature predicts prognosis and therapeutic response in bladder cancer |
title | A novel cuproptosis-related lncRNA signature predicts prognosis and therapeutic response in bladder cancer |
title_full | A novel cuproptosis-related lncRNA signature predicts prognosis and therapeutic response in bladder cancer |
title_fullStr | A novel cuproptosis-related lncRNA signature predicts prognosis and therapeutic response in bladder cancer |
title_full_unstemmed | A novel cuproptosis-related lncRNA signature predicts prognosis and therapeutic response in bladder cancer |
title_short | A novel cuproptosis-related lncRNA signature predicts prognosis and therapeutic response in bladder cancer |
title_sort | novel cuproptosis-related lncrna signature predicts prognosis and therapeutic response in bladder cancer |
topic | Genetics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9845412/ https://www.ncbi.nlm.nih.gov/pubmed/36685947 http://dx.doi.org/10.3389/fgene.2022.1082691 |
work_keys_str_mv | AT caijinming anovelcuproptosisrelatedlncrnasignaturepredictsprognosisandtherapeuticresponseinbladdercancer AT xiehaoran anovelcuproptosisrelatedlncrnasignaturepredictsprognosisandtherapeuticresponseinbladdercancer AT yanyilin anovelcuproptosisrelatedlncrnasignaturepredictsprognosisandtherapeuticresponseinbladdercancer AT huangzhengnan anovelcuproptosisrelatedlncrnasignaturepredictsprognosisandtherapeuticresponseinbladdercancer AT tangpengfei anovelcuproptosisrelatedlncrnasignaturepredictsprognosisandtherapeuticresponseinbladdercancer AT caoxiangqian anovelcuproptosisrelatedlncrnasignaturepredictsprognosisandtherapeuticresponseinbladdercancer AT wangzeyi anovelcuproptosisrelatedlncrnasignaturepredictsprognosisandtherapeuticresponseinbladdercancer AT yangchenkai anovelcuproptosisrelatedlncrnasignaturepredictsprognosisandtherapeuticresponseinbladdercancer AT wenjiling anovelcuproptosisrelatedlncrnasignaturepredictsprognosisandtherapeuticresponseinbladdercancer AT tanmingyue anovelcuproptosisrelatedlncrnasignaturepredictsprognosisandtherapeuticresponseinbladdercancer AT zhangfang anovelcuproptosisrelatedlncrnasignaturepredictsprognosisandtherapeuticresponseinbladdercancer AT shenbing anovelcuproptosisrelatedlncrnasignaturepredictsprognosisandtherapeuticresponseinbladdercancer AT caijinming novelcuproptosisrelatedlncrnasignaturepredictsprognosisandtherapeuticresponseinbladdercancer AT xiehaoran novelcuproptosisrelatedlncrnasignaturepredictsprognosisandtherapeuticresponseinbladdercancer AT yanyilin novelcuproptosisrelatedlncrnasignaturepredictsprognosisandtherapeuticresponseinbladdercancer AT huangzhengnan novelcuproptosisrelatedlncrnasignaturepredictsprognosisandtherapeuticresponseinbladdercancer AT tangpengfei novelcuproptosisrelatedlncrnasignaturepredictsprognosisandtherapeuticresponseinbladdercancer AT caoxiangqian novelcuproptosisrelatedlncrnasignaturepredictsprognosisandtherapeuticresponseinbladdercancer AT wangzeyi novelcuproptosisrelatedlncrnasignaturepredictsprognosisandtherapeuticresponseinbladdercancer AT yangchenkai novelcuproptosisrelatedlncrnasignaturepredictsprognosisandtherapeuticresponseinbladdercancer AT wenjiling novelcuproptosisrelatedlncrnasignaturepredictsprognosisandtherapeuticresponseinbladdercancer AT tanmingyue novelcuproptosisrelatedlncrnasignaturepredictsprognosisandtherapeuticresponseinbladdercancer AT zhangfang novelcuproptosisrelatedlncrnasignaturepredictsprognosisandtherapeuticresponseinbladdercancer AT shenbing novelcuproptosisrelatedlncrnasignaturepredictsprognosisandtherapeuticresponseinbladdercancer |